Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T12475 | ||||
Target Name | Gonadotropin-releasing hormone receptor (GNRHR) | ||||
Type of Target |
Successful |
||||
Drug Potency against Target | Cetrorelix | Drug Info | IC50 = 1.21 nM | [6] | |
ACYLINE | Drug Info | IC50 = 1.5 nM | [3] | ||
AZALINE B | Drug Info | IC50 = 1.4 nM | [3] | ||
LHRH | Drug Info | IC50 = 7 nM | [7] | ||
NBI-42902 | Drug Info | Ki = 5.7 nM | [8] | ||
PGlu-His-Trp-Ser-His-D-Tyr-Leu-Arg-Pro-Gly-NH2 | Drug Info | IC50 = 8.1 nM | [1] | ||
PGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 | Drug Info | IC50 = 4.1 nM | [1] | ||
TAK-013 | Drug Info | IC50 = 0.6 nM | [4] | ||
WAY-207024 | Drug Info | IC50 = 360 nM | [5] | ||
[4Aph(CO-(C2H4O)3-C2H4-NH-CO-NH-OCH3)5]degarelix | Drug Info | IC50 = 1.06 nM | [2] | ||
[4Aph(CO-NH-(C2H4O)2-C2H5)5]degarelix | Drug Info | IC50 = 3.16 nM | [2] | ||
[4Aph(CO-NH-OCH3)5,D-4Aph(CO-NH-OCH3)6]degarelix | Drug Info | IC50 = 0.91 nM | [2] | ||
[4Aph(CO-NH-OCH3)5]degarelix | Drug Info | IC50 = 0.6 nM | [2] | ||
[4Aph(CO-NH-OH)5]degarelix | Drug Info | IC50 = 0.86 nM | [2] | ||
[D-4Aph(CO-NH-(C2H4O)2-C2H5)6]degarelix | Drug Info | IC50 = 0.88 nM | [2] | ||
[D-4Aph(CO-NH-OCH3)6]degarelix | Drug Info | IC50 = 0.51 nM | [2] | ||
[D-4Aph(CO-NH-OH)6]degarelix | Drug Info | IC50 = 0.8 nM | [2] | ||
[D-Dab(CO-NH-OCH3)3]degarelix | Drug Info | IC50 = 1.69 nM | [2] | ||
[D-Dab(CO-NH-OH)3]degarelix | Drug Info | IC50 = 2.68 nM | [2] | ||
[D-Dap(CO-NH-OCH3)3]degarelix | Drug Info | IC50 = 3.16 nM | [2] | ||
[D-Dap(CO-NH-OH)3]degarelix | Drug Info | IC50 = 3.46 nM | [2] | ||
[D-Gln3,D-Ncy(isopropyl)7]acyline | Drug Info | IC50 = 39 nM | [3] | ||
[D-Gln3,D-Ncy(SO,isopropyl)7]acyline | Drug Info | IC50 = 85 nM | [3] | ||
[D-Gln3,D-Ncy(SO2,isopropyl)7]acyline | Drug Info | IC50 = 2004 nM | [3] | ||
[D-Gln3,Ncy(isopropyl)7]acyline | Drug Info | IC50 = 6.2 nM | [3] | ||
[D-Gln3,Ncy(SO,isopropyl)7]acyline | Drug Info | IC50 = 13 nM | [3] | ||
[D-Gln3,Ncy(SO2,isopropyl)7]acyline | Drug Info | IC50 = 3815 nM | [3] | ||
[D-Ncy(2-naphthyl)1]acyline | Drug Info | IC50 = 4.4 nM | [3] | ||
[D-Ncy(isopropyl)7]acyline | Drug Info | IC50 = 0.81 nM | [3] | ||
[D-Ncy(methyl)10] acyline | Drug Info | IC50 = 1.7 nM | [3] | ||
[D-Ncy(methyl)4]acyline | Drug Info | IC50 = 25 nM | [3] | ||
[D-Ncy(SO,isopropyl)7]acyline | Drug Info | IC50 = 3 nM | [3] | ||
[D-Ncy(SO,methyl)10]acyline | Drug Info | IC50 = 0.83 nM | [3] | ||
[D-Ncy(SO,methyl)4]acyline | Drug Info | IC50 = 6.9 nM | [3] | ||
[Ncy(2-naphthyl)1]acyline | Drug Info | IC50 = 2.2 nM | [3] | ||
[Ncy(isopropyl)7]acyline | Drug Info | IC50 = 2.5 nM | [3] | ||
[Ncy(methyl)10]acyline | Drug Info | IC50 = 1.7 nM | [3] | ||
[Ncy(methyl)4]acyline | Drug Info | IC50 = 2.4 nM | [3] | ||
[Ncy(SO,isopropyl)7]acyline | Drug Info | IC50 = 3.2 nM | [3] | ||
[Ncy(SO,methyl)10]acyline | Drug Info | IC50 = 0.87 nM | [3] | ||
[Ncy(SO,methyl)4]acyline | Drug Info | IC50 = 4.6 nM | [3] | ||
References | |||||
REF 1 | Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor. J Med Chem. 2006 Jan 26;49(2):637-47. | ||||
REF 2 | Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43. | ||||
REF 3 | Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. | ||||
REF 4 | Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem. 2008 Jun 26;51(12):3331-48. | ||||
REF 5 | Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2512-5. | ||||
REF 6 | Characterization of gonadotropin-releasing hormone analogs based on a sensitive cellular luciferase reporter gene assay. Anal Biochem. 1997 Aug 15;251(1):17-23. | ||||
REF 7 | Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J Med Chem. 1998 Oct 22;41(22):4190-5. | ||||
REF 8 | Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008 Dec 11;51(23):7478-85. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.